Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01352650 · ClinicalTrials.gov registry record · Phase 1
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT01352650 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 71 participants.
The verdict
NCT01352650, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
The hypothesis of this proposal is that combining plerixafor, an inhibitor of stromal cell derived factor - 1α (SDF-1α), with decitabine, a DNA methyltransferase inhibitor, as induction and postremission therapy for older patients with Acute Myeloid Leukemia (AML) will improve treatment outcomes via mobilization of leukemia stem cells and alteration of the pharmacodynamics of decitabine. The protocol will establish the safety and feasibility of combining two different doses of plerixafor with a fixed dose and schedule of decitabine.
Interventions
- DRUG decitabine
- DRUG plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2011-06-17 |
| Est. Completion | 2016-12-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01352650
The ClinicalTrials.gov registry entry for NCT01352650 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which decitabine is the first listed.
NCT01352650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01352650 about?
NCT01352650 is a clinical study titled "Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)". The hypothesis of this proposal is that combining plerixafor, an inhibitor of stromal cell derived factor - 1α (SDF-1α), with decitabine, a DNA methyltransferase inhibitor, as induction and postremission therapy for older patients with Acute Myeloid Leukemia (AML) will improve treatment outcomes via...
What is the current status of trial NCT01352650?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2011-06-17. Estimated completion is 2016-12-27.
What interventions are being tested in trial NCT01352650?
The interventions under investigation include: decitabine (DRUG), plerixafor (DRUG).
Who is sponsoring clinical trial NCT01352650?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.